Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension

Marlina Manhiani, Jeffrey E. Quigley, Sarah F. Knight, Shiva Tasoobshirazi, Tar Rhonda Moore, Michael W Brands, Bruce D. Hammock, John D. Imig

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Inhibition of soluble epoxide hydrolase (sEH) has been shown to be renal protective in rat models of salt-sensitive hypertension. Here, we hypothesize that targeted disruption of the sEH gene (Ephx2) prevents both renal inflammation and injury in deoxycorticosterone acetate plus high salt (DOCA-salt) hypertensive mice. Mean arterial blood pressure (MAP) increased significantly in the DOCA-salt groups, and MAP was lower in Ephx2-/- DOCA-salt (129 ± 3 mmHg) compared with wild-type (WT) DOCA-salt (145 ± 2 mmHg) mice. Following 21 days of treatment, WT DOCA-salt urinary MCP-1 excretion increased from control and was attenuated in the Ephx2-/-DOCA-salt group. Macrophage infiltration was reduced in Ephx2-/-DOCA-salt compared with WT DOCA-salt mice. Albuminuria increased in WT DOCA-salt (278 ± 55 μ/day) compared with control (17 ± 1 μay) and was blunted in the Ephx2-/- DOCA-salt mice (97 ± 23 μay). Glomerular nephrin expression demonstrated an inverse relationship with albuminuria. Nephrin immunofluorescence was greater in the Ephx2-/- DOCA-salt group (3.4 ± 0.3 RFU) compared with WT DOCA-salt group (1.1 ± 0.07 RFU). Reduction in renal inflammation and injury was also seen in WT DOCA-salt mice treated with a sEH inhibitor {trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; tAUCB}, demonstrating that the C-terminal hydrolase domain of the sEH enzyme is responsible for renal protection with DOCA-salt hypertension. These data demonstrate that Ephx2 gene deletion decreases blood pressure, attenuates renal inflammation, and ameliorates glomerular injury in DOCA-salt hypertension.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume297
Issue number3
DOIs
StatePublished - Sep 1 2009

Fingerprint

Epoxide Hydrolases
Desoxycorticosterone
Gene Deletion
Acetates
Salts
Hypertension
Inflammation
Kidney
Wounds and Injuries
Arterial Pressure
Albuminuria
Benzoic Acid

Keywords

  • Albuminuria
  • Blood pressure
  • Deoxycorticosterone acetate
  • Ephx2
  • Glomerular injury
  • High salt
  • NF-κB

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. / Manhiani, Marlina; Quigley, Jeffrey E.; Knight, Sarah F.; Tasoobshirazi, Shiva; Moore, Tar Rhonda; Brands, Michael W; Hammock, Bruce D.; Imig, John D.

In: American Journal of Physiology - Renal Physiology, Vol. 297, No. 3, 01.09.2009.

Research output: Contribution to journalArticle

Manhiani, Marlina ; Quigley, Jeffrey E. ; Knight, Sarah F. ; Tasoobshirazi, Shiva ; Moore, Tar Rhonda ; Brands, Michael W ; Hammock, Bruce D. ; Imig, John D. / Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. In: American Journal of Physiology - Renal Physiology. 2009 ; Vol. 297, No. 3.
@article{d813629f02754387b6cc4be6ae28e1d3,
title = "Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension",
abstract = "Inhibition of soluble epoxide hydrolase (sEH) has been shown to be renal protective in rat models of salt-sensitive hypertension. Here, we hypothesize that targeted disruption of the sEH gene (Ephx2) prevents both renal inflammation and injury in deoxycorticosterone acetate plus high salt (DOCA-salt) hypertensive mice. Mean arterial blood pressure (MAP) increased significantly in the DOCA-salt groups, and MAP was lower in Ephx2-/- DOCA-salt (129 ± 3 mmHg) compared with wild-type (WT) DOCA-salt (145 ± 2 mmHg) mice. Following 21 days of treatment, WT DOCA-salt urinary MCP-1 excretion increased from control and was attenuated in the Ephx2-/-DOCA-salt group. Macrophage infiltration was reduced in Ephx2-/-DOCA-salt compared with WT DOCA-salt mice. Albuminuria increased in WT DOCA-salt (278 ± 55 μ/day) compared with control (17 ± 1 μay) and was blunted in the Ephx2-/- DOCA-salt mice (97 ± 23 μay). Glomerular nephrin expression demonstrated an inverse relationship with albuminuria. Nephrin immunofluorescence was greater in the Ephx2-/- DOCA-salt group (3.4 ± 0.3 RFU) compared with WT DOCA-salt group (1.1 ± 0.07 RFU). Reduction in renal inflammation and injury was also seen in WT DOCA-salt mice treated with a sEH inhibitor {trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; tAUCB}, demonstrating that the C-terminal hydrolase domain of the sEH enzyme is responsible for renal protection with DOCA-salt hypertension. These data demonstrate that Ephx2 gene deletion decreases blood pressure, attenuates renal inflammation, and ameliorates glomerular injury in DOCA-salt hypertension.",
keywords = "Albuminuria, Blood pressure, Deoxycorticosterone acetate, Ephx2, Glomerular injury, High salt, NF-κB",
author = "Marlina Manhiani and Quigley, {Jeffrey E.} and Knight, {Sarah F.} and Shiva Tasoobshirazi and Moore, {Tar Rhonda} and Brands, {Michael W} and Hammock, {Bruce D.} and Imig, {John D.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1152/ajprenal.00098.2009",
language = "English (US)",
volume = "297",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension

AU - Manhiani, Marlina

AU - Quigley, Jeffrey E.

AU - Knight, Sarah F.

AU - Tasoobshirazi, Shiva

AU - Moore, Tar Rhonda

AU - Brands, Michael W

AU - Hammock, Bruce D.

AU - Imig, John D.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Inhibition of soluble epoxide hydrolase (sEH) has been shown to be renal protective in rat models of salt-sensitive hypertension. Here, we hypothesize that targeted disruption of the sEH gene (Ephx2) prevents both renal inflammation and injury in deoxycorticosterone acetate plus high salt (DOCA-salt) hypertensive mice. Mean arterial blood pressure (MAP) increased significantly in the DOCA-salt groups, and MAP was lower in Ephx2-/- DOCA-salt (129 ± 3 mmHg) compared with wild-type (WT) DOCA-salt (145 ± 2 mmHg) mice. Following 21 days of treatment, WT DOCA-salt urinary MCP-1 excretion increased from control and was attenuated in the Ephx2-/-DOCA-salt group. Macrophage infiltration was reduced in Ephx2-/-DOCA-salt compared with WT DOCA-salt mice. Albuminuria increased in WT DOCA-salt (278 ± 55 μ/day) compared with control (17 ± 1 μay) and was blunted in the Ephx2-/- DOCA-salt mice (97 ± 23 μay). Glomerular nephrin expression demonstrated an inverse relationship with albuminuria. Nephrin immunofluorescence was greater in the Ephx2-/- DOCA-salt group (3.4 ± 0.3 RFU) compared with WT DOCA-salt group (1.1 ± 0.07 RFU). Reduction in renal inflammation and injury was also seen in WT DOCA-salt mice treated with a sEH inhibitor {trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; tAUCB}, demonstrating that the C-terminal hydrolase domain of the sEH enzyme is responsible for renal protection with DOCA-salt hypertension. These data demonstrate that Ephx2 gene deletion decreases blood pressure, attenuates renal inflammation, and ameliorates glomerular injury in DOCA-salt hypertension.

AB - Inhibition of soluble epoxide hydrolase (sEH) has been shown to be renal protective in rat models of salt-sensitive hypertension. Here, we hypothesize that targeted disruption of the sEH gene (Ephx2) prevents both renal inflammation and injury in deoxycorticosterone acetate plus high salt (DOCA-salt) hypertensive mice. Mean arterial blood pressure (MAP) increased significantly in the DOCA-salt groups, and MAP was lower in Ephx2-/- DOCA-salt (129 ± 3 mmHg) compared with wild-type (WT) DOCA-salt (145 ± 2 mmHg) mice. Following 21 days of treatment, WT DOCA-salt urinary MCP-1 excretion increased from control and was attenuated in the Ephx2-/-DOCA-salt group. Macrophage infiltration was reduced in Ephx2-/-DOCA-salt compared with WT DOCA-salt mice. Albuminuria increased in WT DOCA-salt (278 ± 55 μ/day) compared with control (17 ± 1 μay) and was blunted in the Ephx2-/- DOCA-salt mice (97 ± 23 μay). Glomerular nephrin expression demonstrated an inverse relationship with albuminuria. Nephrin immunofluorescence was greater in the Ephx2-/- DOCA-salt group (3.4 ± 0.3 RFU) compared with WT DOCA-salt group (1.1 ± 0.07 RFU). Reduction in renal inflammation and injury was also seen in WT DOCA-salt mice treated with a sEH inhibitor {trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; tAUCB}, demonstrating that the C-terminal hydrolase domain of the sEH enzyme is responsible for renal protection with DOCA-salt hypertension. These data demonstrate that Ephx2 gene deletion decreases blood pressure, attenuates renal inflammation, and ameliorates glomerular injury in DOCA-salt hypertension.

KW - Albuminuria

KW - Blood pressure

KW - Deoxycorticosterone acetate

KW - Ephx2

KW - Glomerular injury

KW - High salt

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=69449093425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449093425&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00098.2009

DO - 10.1152/ajprenal.00098.2009

M3 - Article

C2 - 19553349

AN - SCOPUS:69449093425

VL - 297

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3

ER -